000112477 001__ 112477
000112477 005__ 20230519145434.0
000112477 0247_ $$2doi$$a10.1136/rmdopen-2021-001925
000112477 0248_ $$2sideral$$a127519
000112477 037__ $$aART-2021-127519
000112477 041__ $$aeng
000112477 100__ $$aÁlvaro Gracia, J.M.
000112477 245__ $$aRole of targeted therapies in rheumatic patients on COVID-19 outcomes: Results from the COVIDSER study
000112477 260__ $$c2021
000112477 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112477 5203_ $$aObjectives To analyse the effect of targeted therapies, either biological (b) disease-modifying antirheumatic drugs (DMARDs), targeted synthetic (ts) DMARDs and other factors (demographics, comorbidities or COVID-19 symptoms) on the risk of COVID-19 related hospitalisation in patients with inflammatory rheumatic diseases. Methods The COVIDSER study is an observational cohort including 7782 patients with inflammatory rheumatic diseases. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Antirheumatic medication taken immediately prior to infection, demographic characteristics, rheumatic disease diagnosis, comorbidities and COVID-19 symptoms were analysed. Results A total of 426 cases of symptomatic COVID-19 from 1 March 2020 to 13 April 2021 were included in the analyses: 106 (24.9%) were hospitalised and 19 (4.4%) died. In multivariate-adjusted models, bDMARDs and tsDMARDs in combination were not associated with hospitalisation compared with conventional synthetic DMARDs (OR 0.55, 95% CI 0.24 to 1.25 of b/tsDMARDs, p=0.15). Tumour necrosis factor inhibitors (TNF-i) were associated with a reduced likelihood of hospitalisation (OR 0.32, 95% CI 0.12 to 0.82, p=0.018), whereas rituximab showed a tendency to an increased risk of hospitalisation (OR 4.85, 95% CI 0.86 to 27.2). Glucocorticoid use was not associated with hospitalisation (OR 1.69, 95% CI 0.81 to 3.55). A mix of sociodemographic factors, comorbidities and COVID-19 symptoms contribute to patients'' hospitalisation. Conclusions The use of targeted therapies as a group is not associated with COVID-19 severity, except for rituximab, which shows a trend towards an increased risk of hospitalisation, while TNF-i was associated with decreased odds of hospitalisation in patients with rheumatic disease. Other factors like age, male gender, comorbidities and COVID-19 symptoms do play a role. ©
000112477 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000112477 590__ $$a5.806$$b2021
000112477 592__ $$a1.669$$b2021
000112477 594__ $$a7.1$$b2021
000112477 591__ $$aRHEUMATOLOGY$$b7 / 34 = 0.206$$c2021$$dQ1$$eT1
000112477 593__ $$aImmunology and Allergy$$c2021$$dQ1
000112477 593__ $$aImmunology$$c2021$$dQ1
000112477 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112477 700__ $$aSanchez-Piedra, C.
000112477 700__ $$aManero, J.$$uUniversidad de Zaragoza
000112477 700__ $$aRuiz-Lucea, M.E.
000112477 700__ $$aLópez-Vives, L.
000112477 700__ $$aBohorquez, C.
000112477 700__ $$aMartinez-Barrio, J.
000112477 700__ $$aBonilla, G.
000112477 700__ $$aVela, P.
000112477 700__ $$aGarcía-Villanueva, M.J.
000112477 700__ $$aNavío-Marco, M.T.
000112477 700__ $$aPavía, M.
000112477 700__ $$aGalindo, M.
000112477 700__ $$aErausquin, C.
000112477 700__ $$aGonzalez-Gay, M.A.
000112477 700__ $$aRua-Figueroa, I.
000112477 700__ $$aPego-Reigosa, J.M.
000112477 700__ $$aCastrejon, I.
000112477 700__ $$aSanchez-Costa, J.T.
000112477 700__ $$aGonzález-Dávila, E.
000112477 700__ $$aDiaz-Gonzalez, F.
000112477 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000112477 773__ $$g7, 3 (2021), e001925 [13 pp,]$$tRMD Open$$x2056-5933
000112477 8564_ $$s485445$$uhttps://zaguan.unizar.es/record/112477/files/texto_completo.pdf$$yVersión publicada
000112477 8564_ $$s3151804$$uhttps://zaguan.unizar.es/record/112477/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112477 909CO $$ooai:zaguan.unizar.es:112477$$particulos$$pdriver
000112477 951__ $$a2023-05-18-14:20:36
000112477 980__ $$aARTICLE